zika
viru
mosquitoborn
flaviviru
approxim
kilobas
ribonucl
acid
rna
viru
usual
caus
mild
infect
adult
symptom
includ
fever
arthralgia
howev
sever
complic
occur
hear
loss
current
zika
viru
outbreak
intrauterin
infect
associ
fetal
reliabl
detect
zika
viru
infect
peopl
key
understand
epidemiolog
pathogenesi
altern
transmiss
rout
viru
sexual
intercours
blood
howev
area
zika
viru
cocircul
dengu
chikungunya
virus
physician
reliabl
diagnos
zika
viru
infect
clinic
present
virus
caus
similar
symptom
use
serolog
zika
viru
diagnost
challeng
crossreact
antibodi
elicit
endem
flavivirus
dengu
yellow
fever
st
loui
enceph
west
nile
molecular
detect
viral
nucleic
acid
use
realtim
revers
transcript
rt
polymeras
chain
reaction
pcr
assay
highli
reliabl
diagnost
method
acut
infect
current
six
wide
use
realtim
assay
zika
viru
pan
american
health
organ
paho
recommend
addit
realtim
high
realtim
sensit
import
avoid
falseneg
result
nucleotid
mutat
bind
site
primer
probe
affect
far
genet
variabl
zika
viru
asian
lineag
caus
current
american
outbreak
limit
nucleotid
differ
across
viral
genom
fig
howev
mutat
occur
evenli
across
viral
genom
nucleotid
mismatch
oligonucleotid
sequenc
publish
assay
asian
lineag
consensu
sequenc
alreadi
exist
individu
primer
probe
five
mismatch
fig
note
worstcas
scenario
base
genet
variabl
permit
within
asian
zika
viru
lineag
singl
known
zika
viru
strain
accumul
mismatch
howev
increas
number
diverg
zika
viru
outbreak
strain
highlight
genet
variabl
potenti
limit
factor
sensit
zika
viru
realtim
diagnost
compar
sensit
publish
realtim
assay
two
new
assay
design
less
nucleotid
mismatch
current
outbreak
strain
also
present
data
viral
load
profil
blood
urin
infect
patient
use
one
new
assay
compar
nine
differ
assay
includ
zika
viru
realtim
assay
publish
april
assay
target
membran
envelop
e
nonstructur
protein
ns
genom
design
two
new
assay
cover
current
known
zika
viru
genet
variabl
e
genom
domain
tabl
novel
assay
show
four
potenti
mismatch
per
assay
fig
design
avoid
mismatch
critic
region
oligonucleotid
affect
primer
bind
new
assay
addit
design
allow
crossdetect
spondweni
viru
closest
rel
zika
viru
region
conserv
relat
viru
taxa
expect
less
variat
genom
region
control
base
current
zika
viru
outbreak
strain
access
number
posit
control
gener
five
assayspecif
quantifi
vitro
transcript
ivt
respect
genom
target
region
data
analyt
sensit
includ
standard
measur
lower
limit
detect
avail
publish
assay
enabl
stoichiometr
exact
analys
lower
limit
detect
assay
join
target
domain
quant
univers
control
ribonucl
acid
uncrna
contain
assay
target
region
one
rna
strand
fig
tabl
control
acquir
via
european
viru
archiv
follow
link
zika
viru
ivt
avail
http
wwweuropeanvirusarchivecomportalproduitphp
zika
viru
ivt
ii
avail
http
wwweuropeanvirusarchivecomportalproduitphp
zika
viru
ivt
iii
avail
http
wwweuropeanvirusarchivecomportalproduitphp
zika
viru
ivt
iv
avail
http
wwweuropeanvirusarchivecomportalproduitphp
zika
viru
ivt
v
avail
http
wwweuropeanvirusarchivecomportalproduitphp
uncrna
avail
http
wwweuropeanvirusarchivecomportalproduitphp
uncrna
gener
describ
brief
uncrna
custom
design
fragment
promotor
sequenc
integr
dna
technolog
leuven
belgium
vitro
disadvantag
use
test
control
high
concentr
viral
rna
eg
cell
cultur
potenti
laboratori
contamin
potenti
caus
falseposit
test
result
contrast
natur
viral
rna
potenti
case
laboratori
contamin
uncrna
proven
two
realtim
marker
assay
design
specif
detect
uncrna
tabl
two
marker
assay
contain
detect
probe
target
overlap
two
join
genom
target
domain
natur
occur
zika
viru
genom
fig
purifi
viral
rna
use
qiagen
viral
rna
mini
kit
qian
hilden
germani
magna
pure
viral
na
small
volum
kit
roch
basel
switzerland
accord
manufactur
instruct
dengu
viru
rna
quantif
flaviviru
type
done
describ
experi
except
assess
threshold
cycl
variat
use
differ
reaction
condit
thermocycl
quantifi
zika
viru
rna
use
instrument
ii
roch
basel
switzerland
gener
reaction
set
rna
reaction
buffer
iii
one
step
system
taq
polymeras
thermo
fisher
scientif
darmstadt
germani
mm
magnesium
sulfat
solut
thermo
fisher
scientif
nonacetyl
bovin
serum
albumin
roch
nm
primer
nm
probe
iii
taq
mix
amplif
involv
minut
follow
minut
cycl
second
second
second
comparison
ct
valu
use
differ
pcr
cycler
chemistri
use
bonn
e
assay
use
either
superscript
iii
onestep
kit
thermo
fischer
onestep
kit
qiagen
roch
lightcycl
qiagen
rotor
gene
hq
appli
biosystem
thermocycl
refer
condit
refer
usag
life
technolog
iii
onestep
enzym
mix
roch
thermocycl
describ
probit
regress
analys
determin
lower
limit
detect
realtim
assay
done
use
spss
ibm
ehningen
germani
eight
parallel
test
replic
obtain
clinic
specimen
travel
routin
medic
investig
either
zika
dengu
viru
request
due
compat
clinic
symptom
travel
histori
affect
countri
travel
acquir
infect
brazil
dominican
republ
surinam
spike
zika
virusneg
human
plasma
urin
sampl
defin
quantiti
african
zika
viru
strain
asian
lineag
outbreak
strain
spike
sampl
serial
dilut
two
replic
dilut
individu
purifi
use
magna
pure
viral
na
small
volum
kit
input
volum
extract
volum
assayspecif
ivt
uncrna
allow
compar
quantif
zika
viru
rna
mean
twofold
deviat
result
maximum
deviat
sixfold
suggest
abil
use
control
gener
compar
result
even
differ
realtim
assay
use
differ
laboratori
two
marker
assay
show
detect
zika
viru
rna
even
upon
use
rna
hightitr
cell
cultur
isol
rna
copiesml
realtim
templat
ensur
specif
detect
zika
viru
evalu
assay
use
hightitr
cell
cultur
isol
differ
flavivirus
chikungunya
viru
list
test
isol
avail
correspond
author
none
publish
assay
detect
cocircul
alphaviru
chikungunya
viru
flaviviru
expect
asian
zika
viru
lineagespecif
ebas
detect
african
lineag
despit
high
concentr
viral
rna
sampl
intend
new
assay
crossdetect
spondweni
viru
well
kokobera
jugra
viru
virus
predominantli
circul
latin
america
henc
affect
peopl
current
zika
viru
determin
lower
limit
detect
use
uncrna
two
assay
show
compar
high
analyt
sensit
around
zika
viru
rna
copiesreact
fig
assay
recommend
paho
show
lower
limit
detect
wherea
assay
show
lower
limit
detect
exemplifi
impact
technic
sensit
clinic
sensit
extrapol
lower
limit
detect
clinic
viral
load
shown
tabl
assay
lower
limit
detect
copiesreact
clinic
detect
limit
copiesml
wherea
assay
lower
limit
detect
copiesreact
clinic
detect
limit
copiesml
improv
clinic
sensit
rna
purif
method
could
optim
use
larger
input
volum
clinic
sampl
tabl
examin
assay
sensit
differ
clinic
specimen
incorpor
step
rna
purif
use
zika
virusneg
human
blood
urin
sampl
spike
copiesml
either
zika
viru
repres
asian
lineag
strain
african
lineag
strain
result
consist
lower
limit
detect
uncrna
assay
high
analyt
sensit
could
detect
zika
viru
rna
copiesml
blood
urin
least
one
replic
experi
wherea
assay
lowest
analyt
sensit
yield
neg
result
even
high
zika
viru
concentr
copiesml
fig
explor
variabl
threshold
cycl
ct
valu
could
vari
due
pcr
instrument
reagent
use
test
two
new
assay
divers
reaction
condit
includ
reagent
differ
supplier
differ
realtim
instrument
even
variat
two
variabl
could
yield
cycl
differ
ct
valu
viru
target
concentr
correspond
deviat
viral
load
result
fig
therefor
use
ct
valu
comparison
viral
load
studi
might
accord
preliminari
studi
shortterm
viremia
low
viral
load
complic
zika
viru
detect
sinc
zika
viru
rna
detect
urin
zika
virusinfect
patient
two
week
investig
whether
blood
urin
suitabl
clinic
specimen
diagnos
acut
zika
viru
infect
use
new
assay
quantifi
viral
load
serum
sampl
urin
sampl
patient
infect
viru
strain
current
outbreak
shown
fig
viral
load
gener
decreas
day
symptom
onset
match
urin
blood
sampl
taken
day
avail
six
patient
one
patient
lower
viral
load
urin
blood
two
patient
equal
viral
load
sampl
three
patient
higher
viral
load
urin
blood
fig
mean
viral
load
avail
clinic
sampl
includ
without
known
date
symptom
onset
rna
copiesml
blood
rang
rna
copiesml
urin
rang
viral
load
specimen
sampl
first
day
symptom
onset
compar
viral
load
serum
patient
sampl
zika
viru
outbreak
feder
state
fig
combin
data
set
sampl
compris
data
outbreak
sampl
studi
sampl
result
mean
viral
load
rna
copiesml
blood
rang
rna
copiesml
urin
rang
sampl
taken
compar
interv
within
day
symptom
onset
urin
within
day
symptom
onset
serum
sampl
two
sampl
contain
viral
load
less
rna
copiesml
fig
lead
estim
risk
falseneg
test
result
even
use
highli
sensit
assay
technic
lower
limit
detect
copiesreact
equival
copiesml
fig
tabl
use
insensit
assay
lower
limit
detect
copiesreact
proport
estim
falseneg
test
result
fig
mani
laboratori
countri
affect
current
outbreak
conduct
zika
viru
test
also
experi
detect
quantifi
dengu
viru
compar
risk
falseneg
test
result
two
virus
quantifi
clinic
sampl
posit
dengu
sent
laboratori
medic
diagnost
previous
mean
viral
load
dengu
rna
copiesml
rang
fig
mean
viral
load
dengu
blood
gener
higher
viral
load
zika
viru
ttest
p
accordingli
estim
risk
falseneg
result
severalfold
lower
dengu
zika
viru
fig
fig
studi
provid
guidanc
choic
method
diagnos
zika
viru
infect
molecular
control
enabl
comparison
result
differ
laboratori
studi
low
viral
load
present
previou
suggest
possibl
falseneg
test
result
use
realtim
assay
diagnost
result
present
suggest
publish
realtim
assay
may
limit
use
clinic
diagnost
current
zika
viru
outbreak
one
assay
intend
viru
type
use
diagnost
low
assay
featur
potenti
limit
use
current
outbreak
includ
limit
access
specif
probe
format
eg
fay
assay
rel
lower
analyt
sensit
high
number
potenti
mismatch
member
asian
zika
viru
novel
assay
may
robust
genet
variat
realtim
monitor
assay
oligonucleotid
bind
region
requir
current
situat
accord
data
lanciotti
pyke
e
bonn
e
bonn
assay
highli
sensit
asian
zika
viru
lineag
show
mismatch
within
genom
domain
target
assay
present
knowledg
zika
viru
variabl
suggest
laboratori
use
five
assay
diagnost
current
outbreak
prefer
combin
least
two
assay
increas
clinic
low
viral
load
detect
urin
blood
sampl
agreement
two
previou
studi
report
quantit
contrast
data
six
patient
french
observ
signific
differ
viral
load
urin
blood
sampl
henc
data
support
urin
gener
suitabl
clinic
specimen
detect
zika
viru
howev
sinc
zika
viru
rna
seem
remain
detect
urin
semen
longer
suggest
blood
urin
sampl
use
reliabl
zika
viru
diagnost
zika
viru
also
detect
could
evalu
suitabl
saliva
sampl
access
sampl
although
commerci
diagnost
realtim
reagent
zika
viru
detect
avail
laboratori
area
affect
zika
viru
outbreak
often
use
noncommerci
formul
resourc
noncommerci
assay
difficult
standard
compar
transfer
essenti
reagent
coordin
implement
laboratori
protocol
practic
train
staff
strengthen
accur
realtim
diagnost
resourceconstrain
among
essenti
contribut
technolog
transfer
provis
standard
control
materi
ship
intern
without
biosafeti
concern
research
consortia
public
health
structur
use
reagent
establish
technic
basi
test
implement
demonstr
sever
acut
respiratori
syndrom
middl
east
respiratori
virus
emerg
novel
new
diagnost
test
develop
along
provis
reagent
laboratori
howev
detect
zika
viru
test
formul
alreadi
avail
assay
standard
work
provis
refer
reagent
univers
applic
assay
uncrna
reagent
multicentr
valid
natur
viru
standard
quantit
compar
studi
enabl
rel
estim
transmiss
risk
associ
blood
transfus
solid
organ
transplant
well
transmiss
risk
bodi
fluid
semen
saliva
quantit
data
may
also
shed
light
zika
viru
pathogenesi
sinc
higher
viral
load
may
associ
sever
clinic
complic
shown
arbovir
infect
caus
dengu
chikungunya
crimeancongo
haemorrhag
fever
low
viral
load
patient
impli
high
risk
falseneg
test
result
april
suspect
zika
viru
case
could
laboratoryconfirm
paho
low
number
confirm
case
could
due
difficulti
process
high
number
diagnost
request
resourceconstrain
set
studi
puerto
rico
show
patient
suspect
zika
viru
diseas
could
laboratoryconfirm
use
molecular
serolog
addit
studi
brazil
demonstr
patient
suspect
zika
viru
infect
posit
realtim
higher
proport
laboratoryconfirm
case
studi
data
suggest
consider
proport
patient
low
viral
load
may
gone
undiagnos
molecular
test
current
outbreak
endem
countri
also
need
highli
sensit
molecular
zika
viru
detect
method
ensur
safe
blood
transfus
zika
viru
detect
blood
donor
previou
transfusionassoci
transmiss
report
comparison
blood
viral
load
realtim
sensit
suggest
risk
falseneg
result
pool
even
individu
blood
donor
screen
risk
report
west
nile
viru
sever
peopl
acquir
viru
blood
transfus
solid
organ
transplant
falseneg
realtim
associ
zika
viru
infect
fetal
malform
demand
reliabl
zika
viru
diagnost
pregnant
current
sensit
realtim
assay
suggest
molecular
test
pregnanc
may
preferenti
diagnos
highli
virem
pregnant
women
intrauterin
zika
viru
infect
congenit
malform
correl
posit
high
zika
viru
concentr
limit
test
sensit
might
influenc
estim
manifest
index
congenit
diseas
low
viral
load
mani
patient
suggest
limit
capac
molecular
protocol
exclud
zika
viru
infect
highli
affect
area
henc
cohort
studi
investig
zika
viru
pathogenesi
pregnant
women
need
addit
serolog
test
conclus
data
emphas
need
highli
sensit
assay
molecular
zika
viru
diagnost
addit
appropri
choic
method
clinic
sensit
increas
test
sever
specimen
per
patient
use
one
realtim
target
optim
rna
purif
clinic
sampl
combin
molecular
serolog
uncrna
reagent
use
univers
quantit
posit
control
ensur
high
sensit
good
compar
qualit
quantit
result
diagnost
laboratori
clinic
studi
